Biodrugs

Papers
(The H4-Index of Biodrugs is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond238
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry128
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor87
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making75
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome75
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery57
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis53
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis50
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design48
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?37
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy37
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202235
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart32
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies32
Acknowledgement to Referees31
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials30
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic30
CAR-T Cells and the Kidney: Insights from the WHO Safety Database29
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy29
Progress and Challenges in the Treatment of Fabry Disease28
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review28
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?28
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase27
Malaria Vaccines: Progress to Date26
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data26
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer25
0.23763298988342